Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Banyan Biomarkers Inc.

This article was originally published in Start Up

Executive Summary

For acute brain injury patients, the lack of any reliable biological markers makes it nearly impossible to design trials with any precision. Banyan Biomarkers believes it may hold the key to successful development of traumatic brain injury drugs with its diagnostic blood test-based biomarkers for calpain and caspese-enzymes released by dissolving dead and dying brain cells into the blood.
Advertisement

Related Content

Treating Traumatic Brain Injury
Start-Up Previews (01/07)
Treating Traumatic Brain Injury
Start-Up Previews (01/07)

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC091319

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel